PHARMACEUTICAL PREPARATIONS TREAT INFLAMMATORY

Brand Owner (click to sort) Address Description
ALYDA WYETH 235 East 42nd Street New York NY 10017 pharmaceutical preparations to treat inflammatory and autoimmune diseases and disorders, infectious diseases, metabolic diseases and disorders, diseases and disorders of the central nervous system; cardiovascular treatment preparations; oncology treatment preparations; preparations for the prevention and treatment of osteoporosis; vaccines;
ARPAZ WYETH 235 East 42nd Street New York NY 10017 pharmaceutical preparations to treat inflammatory and autoimmune diseases and disorders, infectious diseases, metabolic diseases and disorders, diseases and disorders of the central nervous system; cardiovascular treatment preparations; oncology treatment preparations; preparations for the prevention and treatment of osteoporosis; vaccines;
LENIVEL WYETH 235 East 42nd Street New York NY 10017 pharmaceutical preparations to treat inflammatory and autoimmune diseases and disorders, infectious diseases, metabolic diseases and disorders, diseases and disorders of the central nervous system; cardiovascular treatment preparations; oncology treatment preparations; preparations for the prevention and treatment of osteoporosis; vaccines;
LENIVEL WYETH 235 East 42nd Street New York NY 10017 Pharmaceutical preparations to treat inflammatory and autoimmune diseases and disorders, infectious diseases, metabolic diseases and disorders, diseases and disorders of the central nervous system; cardiovascular treatment preparations; oncology treatment preparations; preparations for the prevention and treatment of osteoporosis; vaccines;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for treating secretory diarrhea. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients, and/or diluents.